Why Agenus Stock Took Flight in May
Agenus (NASDAQ: AGEN), a small-cap immunotherapy company, saw its stock gain a healthy 51% during the month of May, according to data from S&P Global Market Intelligence. The biotech's shares perked up late last month in response to a positive clinical update for its cancer immunotherapy pipeline presented at the American Society for Clinical Oncology (ASCO) annual meeting.
The big draw for investors last month was the news that Agenus' experimental checkpoint inhibitor AGEN1181 may turn out to be a best-in-class product. In an early-stage trial, AGEN1181 produced a 70% clinical benefit in patients with various solid tumors.
Image source: Getty Images.
Source Fool.com
